GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

tildacerfont   Click here for help

GtoPdb Ligand ID: 14043

Synonyms: Example 16 [WO2008036579A1] | LY-2371712 | LY2371712 | SPR-001 | SPR001
Compound class: Synthetic organic
Comment: Tildacerfont is a corticotropin-releasing factor (CRF) receptor antagonist. It is proposed to reduce the overproduction of androgens in people with congenital adrenal hyperplasia (CAH), by targeting CRF1 receptor-mediated ACTH secretion. It was designed to address the lipophilicity and associated toxicity liability observed for earlier molecules.
The IUPAC provided for tildacerfont's INN record generates the molecule with the chemical structure shown here and this is same the structure that is associated with CAS registry ID 1014983-00-6 (also provided in the INN record). This has a slightly different structure on the thiazole ring compared to PubChem's entry for tildacerfont (CID 134694266).
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 78.09
Molecular weight 419.97
XLogP 3.52
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCC(CC)C1=CC(=NC2=C(C(=NN12)C)C3=C(Cl)N=C(N4CCOCC4)S3)C
Isomeric SMILES ClC=1N=C(SC1C=2C(=NN3C2N=C(C=C3C(CC)CC)C)C)N4CCOCC4
InChI InChI=1S/C20H26ClN5OS/c1-5-14(6-2)15-11-12(3)22-19-16(13(4)24-26(15)19)17-18(21)23-20(28-17)25-7-9-27-10-8-25/h11,14H,5-10H2,1-4H3
InChI Key XVAWSBAQNIXMIO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Progressed to clinical evaluation in CAH [2]. However failure to meet primary and secondary endpoints in additional phase 2 studies led to development being discontinued.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03687242 Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia Phase 2 Interventional Spruce Biosciences
NCT03257462 Study of SPR001 in Adults with Classic Congenital Adrenal Hyperplasia Phase 2 Interventional Spruce Biosciences
NCT04457336 A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH Phase 2 Interventional Spruce Biosciences